Drugdiscovery >> Drugs >> News
12357
Views
title
New drug for treating myeloma approved in Europe - drugdiscovery.com


The European Commission has granted approval for Celgene’s drug pomalidomide for the treatment of relapsed and refractory multiple myeloma, in combination with dexamethasone. The marketing name of the drug is Imnovid.
Read More >>


Tags: Celgene, pomalidomide, multiple myeloma,Imnovid,the European Commission approval - August 10, 2013
Related Articles
6256
Views
First biosimilar mAb therapy approved in Europe First biosimilar mAb therapy approved in Europe
Hospira’s Inflectra, monoclonal antibody (mAb) therapy, a biosimilar to Remicade (infliximab), has been approved by the European Commission (EC) for the treatment of inflammatory conditions includin Read More >>

Tags: Hospira, Inflectra, infliximab, Remicade, biosimilar, monoclonal antibody, inflamatory conditions, treatment, Europe

7308
Views
Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe
The European Commission has granted marketing authorization for afatinib, used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC Read More >>

Tags: Giotrif, afatinib, locally advanced, metastatic, non-small cell lung cancer, NSCLC, EGFR mutation, EU, Europe

10728
Views
Another Sanofi MS drug approved in EU Another Sanofi MS drug approved in EU
After Aubagio, Lemtrada - another Sanofi’s drug for treatment of multiple sclerosis has been approved by the European Commission. Read More >>

Tags: multiple sclerosis, Europe, new drug, Aubagio, Lemtrada

8405
Views
Takeda's schizophrenia drug lurasidone approved in Swiss Takeda's schizophrenia drug lurasidone approved in Swiss
This is the first approval in Europe for lurasidone, which is already marketed as Latuda for schizophrenia and bipolar depression in the US and Canada. Read More >>

Tags: lurasidone, latuda, drug, schizophrenia, bipoloar disorder, Swiss, approval, Europe

12524
Views
Teva’s drug for treating neutropenia approved in EU Teva’s drug for treating neutropenia approved in EU
Teva got EU market authorization for the drug Lonquex (lipegfilgrastim) , which is used for reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing c Read More >>

Tags: Teva, lonquex, Neulasta, EMA, EU, approval,febrile neutropenia, neutropenia, cancer patients, patients undergoing chemotherapy

6424
Views
Remicade Copies Approved in Europe Remicade Copies Approved in Europe
J&J’s Remicade, a drug for arthritis, will have cheaper versions made and sold by two other companies in Europe by 2014. Read More >>

Tags: Remicade, Arthritis, Celltrion, Hospira

4764
Views
Revlimid, a promising drug for asymptomatic myeloma? Revlimid, a promising drug for asymptomatic myeloma?
The myeloma community has been encouraged by a new study of Celgene Corp's Revlimid which shows its effectiveness in patients whose disease has not yet progressed. Read More >>

Tags: Revlimid, asymptomatic smouldering multiple myeloma

7104
Views
Velcade approved as a first line therapy in EU Velcade approved as a first line therapy in EU
Johnson & Johnson's multiple myeloma treatment Velcade (bortezomib) has been used in advanced patients and those who were ineligible for stem cell transplantation. In the future, it will also be used Read More >>

Tags: Velcade, multiple myeloma, Johnson & Johnson, approval, EC, EU

4314
Views
Europe-wide cancer research collabortion is announced Europe-wide cancer research collabortion is announced
European institutions announced a collaboration for cancer research. CRT and Nuevolution says, this going to help to delvelop a trustable cure for as wide range of cancer types. Read More >>

Tags: CRT, Nuevolution, cancer, drug

4163
Views
Orexigen seeks approval for obesity drug Contrave in EU Orexigen seeks approval for obesity drug Contrave in EU
If approved after an eagerly-anticipated interim analysis of a cardiovascular outcomes trial called the Light study, the drug might be launched in EU in early 2015. Contrave (naltrexone/bupropion) i Read More >>

Tags: Orexigen, EU, Europe, Contrave, drug, obesity, depression, cravings

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013